The cobas EGFR Mutation Test ("cobas EGFR test", Roche Molecular Systems, Inc, Branchburg, NJ, USA) is a CE-IVD marked multiplex assay that uses allele-specific polymerase chain reaction (AS-PCR) to detect 41 mutations in exons 18, 19, 20, and 21 in FFPET specimens of human NSCLC.
7 A variety of molecular platforms exist for determining the presence of BRAFV600E mutation in formalin-fixed paraffin-embedded (FFPE) tissue samples of melanoma, including pyrosequencing, the cobas BRAF V600 mutation test developed by Roche, and next-generation sequencing platforms.
Eligible patients had unresectable stage III or stage IV melanoma harboring the BRAF-V600E mutation, as determined by the cobas 4800 BRAF V600 mutation test.
Serum NSE values (Elecsys NSE test, Cobas® analyzer) were assessed at H24 and H72 after cardiac arrest.
Study design: The clinical material consisted of 253 consecutive blood samples was tested using a quantitative polymerase chain reaction test, Cobas Amplicor CMV Monitor (Roche) and pp65 antigenemia assay.
Regarding commercial tests, Cobas Core EIA® (Roche, Mannheim, Germany) and FlexSure®HP Serum Test (SmithKlineDiagnostics Palo Alto, CA, USA) were the tests most frequently evaluated (Figure 2A y B).
In this current study, the analytical performance of the cobas KRAS Mutation Test was compared with Sanger sequencing and the ARMS-Scorpion therascreen test using a blinded panel of FFPET tumour specimens of CRC as well as artificial DNA blends.
KRAS mutational status was determined using the Cobas KRAS Mutation Test kit (Roche Molecular Diagnostics, Branchburg, NJ, USA) following manufacturer's procedures.
The cobas EGFR Mutation Test is a sensitive, accurate, rapid, and reproducible assay.
We conducted a two-site comparison of two commercial KRAS mutation kits – the cobas KRAS Mutation Test and the Qiagen therascreen KRAS Kit – and Sanger sequencing.
Until recently, the only FDA-approved BRAF c.1799 T > A mutation detection test was the Cobas 4800 BRAF V600 Mutation Test.
